Strategic supplier partnership with Europlaz Technologies Ltd underpins continuity of supply and Ori’s readiness to serve cell therapy programs at all stages, worldwide
LONDON, UK, and Southminster UK November 11, 2026 – Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, and Europlaz (EPZ), a leading UK contract manufacturer in GMP grade bioprocessing tools and equipment, today announced a strategic partnership to support Ori delivering its GMP-ready IRO® consumable family to cell and gene therapy developers worldwide.
Ori’s partnership with Europlaz supports growing demand for IRO® consumables from leading academic medical centers, CDMOs and biopharma companies as they move cell therapy programs from clinical development toward approval and commercial scale. IRO® consumables are clean injection molded and clean assembled in an ISO 7 cleanroom environment under an ISO 13485 quality management system. The partnership establishes a flexible, scalable and uninterrupted manufacturing infrastructure to meet ongoing supply and future development needs of Ori’s customers, which is critical to clinical and commercial success.
Consumable shortages elsewhere in the industry have shown how supply chain risk can derail development timelines, commercial launch readiness and put patients at risk. For Ori’s partners, security of supply is a critical factor, and Ori has built its operations accordingly, with a qualified and actively monitored supply chain, formal business continuity plans and a structured supply risk management program that spans suppliers, sites, logistics and critical materials globally.
“Cell therapies are made for one individual patient, so there is no room for a gap in the supply chain that derails that patient’s treatment. A delay in a single critical consumable can mean a delay in treatment for someone whose life is in the balance. That is why continuity of supply is a such high priority for Ori,” said Jason C. Foster, CEO, Ori Biotech.
“Our IRO® consumables are produced to GMP-grade standards through our manufacturing partner Europlaz, with robust quality oversight and control at every stage. Europlaz has long experience supplying leading global bioprocessing companies, and together we are expanding manufacturing capacity to be ready for significant global volumes as part of several new partnerships Ori has signed in 2026. Developers and manufacturers can count on receiving the IRO consumables they depend on, consistently and when they need them, so they can focus on getting their therapies to the patients in need.”
Supporting Security of Supply
Europlaz has provided development and design for manufacturing services to Ori since 2023, with this partnership set to create dedicated cleanroom space, access to world class equipment, material holding and best-in-class inventory management. Manufacturing resilience is only as strong as the quality systems that underpin it. Ori and Europlaz apply defined quality metrics, structured inspection arrangements, monitoring of particulates and bioburden, together with oversight across the upstream supply chain, with documented change controls so that partners are immediately informed of any change that could affect their process. Supplier tracking and reporting systems give ongoing visibility into supply chain performance and highlight opportunities to improve lead times and reduce costs, and these controls are designed to support partners in supplier qualification and regulatory submissions.
Ian Goodacre, Technical Director at Europlaz said: “Our simple goal is to make sure the quality consumables Ori, and their customers, need are available and fit for use on time, every time. We have a decades-long track record of helping companies scale up production across medtech and life sciences and are proud to with Ori Biotech to deliver flexible capacity, industry-leading quality and ongoing engineering support from our team of experts.”
As more IRO® partners advance toward commercial manufacture, this partnership reflects the maturity of Ori’s global operations and a shared mission to deliver the operational infrastructure needed to enable widespread patient access to potentially life-saving cell and gene therapies, both consistently and without interruption.
About Ori Biotech
Ori Biotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori’s next-generation manufacturing platform automates better biology, accelerates product development and enables therapy developers to scale their products’ clinical and commercial impact by seamlessly transitioning from R&D to GMP on one platform. The IRO platform has received FDA Advanced Manufacturing Technology (AMT) designation, recognizing it as a leading next-generation solution for cell and gene therapy manufacturing.
For news and updates, visit oribiotech.com/news-insights.